Katrina J. Church Sells 2,535 Shares of Bioventus Inc. (NYSE:BVS) Stock

Bioventus Inc. (NYSE:BVS) SVP Katrina J. Church sold 2,535 shares of Bioventus stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $10.53, for a total value of $26,693.55. Following the completion of the sale, the senior vice president now directly owns 47,264 shares in the company, valued at approximately $497,689.92. The trade was a 5.09 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Bioventus Trading Up 3.0 %

Bioventus stock traded up $0.32 during trading on Thursday, hitting $11.00. The company had a trading volume of 255,781 shares, compared to its average volume of 391,340. The company’s 50 day simple moving average is $11.89 and its 200-day simple moving average is $9.76. Bioventus Inc. has a 1-year low of $3.90 and a 1-year high of $14.38. The company has a current ratio of 1.41, a quick ratio of 0.99 and a debt-to-equity ratio of 1.85. The stock has a market cap of $892.71 million, a price-to-earnings ratio of -18.03 and a beta of 0.79.

Bioventus (NYSE:BVS) last posted its earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share for the quarter, hitting the consensus estimate of $0.06. The firm had revenue of $138.96 million during the quarter, compared to analysts’ expectations of $132.57 million. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. During the same quarter in the previous year, the business earned $0.05 earnings per share. As a group, analysts expect that Bioventus Inc. will post 0.41 EPS for the current fiscal year.

Institutional Investors Weigh In On Bioventus

Hedge funds have recently modified their holdings of the company. Charles Schwab Investment Management Inc. increased its stake in shares of Bioventus by 38.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 390,162 shares of the company’s stock valued at $4,662,000 after acquiring an additional 109,359 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in Bioventus by 100.7% in the second quarter. Dimensional Fund Advisors LP now owns 117,496 shares of the company’s stock valued at $676,000 after purchasing an additional 58,954 shares during the period. Rhumbline Advisers raised its stake in Bioventus by 5,367.9% during the second quarter. Rhumbline Advisers now owns 52,437 shares of the company’s stock worth $302,000 after purchasing an additional 51,478 shares during the period. Segall Bryant & Hamill LLC purchased a new position in Bioventus during the third quarter worth approximately $4,515,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Bioventus in the 3rd quarter valued at $788,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. JPMorgan Chase & Co. upgraded Bioventus from an “underweight” rating to a “neutral” rating and increased their target price for the stock from $12.00 to $13.00 in a research note on Tuesday, December 17th. Craig Hallum increased their target price on shares of Bioventus from $12.00 to $17.00 and gave the company a “buy” rating in a research report on Friday, September 27th. Finally, Canaccord Genuity Group upped their price objective on shares of Bioventus from $12.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, November 6th.

About Bioventus

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.